Clinical Research Directory

Inclusion Criteria: * Age 70 years * Histological diagnosis of Renal Cell Carcinoma (any histology, with the exclusion of urothelial carcinomas) * Locally advanced disease or metastatic disease (any site, measurable or non- measurable lesions), progressing after at least one line of VEGFR-targeted therapy (as per official registration of the drug at AIFA, in case of extension to first-line treatment, TKI-naïve patients will also be eligible), with or without previous exposure to check-point inhibitors. * Life expectancy of at least 3 months * Adequate hepatic, renal and bone marrow function as judged by the treating oncologist. * Written informed consent Exclusion Criteria: * Inability to swallow cabozantinib tablets * Serious comorbidities or cognitive impairment, which may interfere with cabozantinib administration and/or patient's follow up, as judged by the treating physician * Absence of a reliable caregiver, as judged by the treating physician